J&J asks MHRA for antifungal switch
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson's McNeil division requests the U.K. Medicines and Healthcare products Regulatory Agency switch its antifungal Daktarin Intensiv Cream (ketoconazole 2%) from pharmacy to general sale list status. The same active ingredient is found in J&J's Nizoral Anti-dandruff Shampoo which has been GSL in the U.K. since 2001 and switched to U.S. OTC sale in 1997 (1"The Tan Sheet" Jan. 28, 2002)
You may also be interested in...
Johnson & Johnson President Brings Extensive McNeil Background To Post
Johnson & Johnson's appointment of James Lenehan, 53, as president signals a strong commitment by the company to its consumer products segments, despite the firm's shift in emphasis toward its pharmaceutical business over the past ten years
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.